Disease · MONDO_0004958
oral cavity squamous cell carcinoma
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. oral cavity squamous cell carcinoma. Diseases, record MONDO_0004958. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004958
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
OSCC, mouth scc, mouth squamous cell carcinoma, oral cavity scc, oral cavity squamous cell cancer, oral squamous cell carcinoma, scc of mouth, scc of oral cavity, scc of the mouth, scc of the oral cavity, squamous cell carcinoma of mouth, squamous cell carcinoma of oral cavity, squamous cell carcinoma of the mouth, squamous cell carcinoma of the oral cavity
- Open Targets
- Highest stage of its drugs
- Phase 3, for 19 of its 68 drugs, from ClinicalTrials.gov and TTD
- Open Targets
Drugs68
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 3 | ClinicalTrials.gov | 36 | 36 | 36 | Drugs and targets |
| PACLITAXEL | CHEMBL428647 | Small molecule | Phase 3 | ClinicalTrials.gov | 23 | 23 | 21 | Drugs and targets |
| DOCETAXEL | CHEMBL3545252 | Small molecule | Phase 3 | ClinicalTrials.gov | 15 | 15 | 15 | Drugs and targets |
| FLUOROURACIL | CHEMBL185 | Small molecule | Phase 3 | ClinicalTrials.gov | 11 | 11 | 11 | Drugs and targets |
| TISLELIZUMAB | CHEMBL4297840 | Antibody | Phase 3 | ClinicalTrials.gov | 8 | 8 | 7 | Drugs and targets |
| CAMRELIZUMAB | CHEMBL4297715 | Antibody | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| SINTILIMAB | CHEMBL4297829 | Antibody | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| PLATINUM | CHEMBL1235478 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 2 | Drugs and targets |
| ALDESLEUKIN | CHEMBL1201438 | Protein | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
1 to 10 of 68
See all 68 drugsTargets114
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| PDCD1 | Programmed cell death protein 1 | 8 | Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor | Phase 3 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| EGFR | Epidermal growth factor receptor | 6 | Epidermal growth factor receptor erbB1 inhibitor | Phase 3 | https://conductscience.org/library/genes/1956 | Drugs and targets |
| CD274 | Programmed cell death 1 ligand 1 | 4 | Programmed cell death 1 ligand 1 inhibitor; Programmed cell death 1 ligand 1 other | Phase 3 | https://conductscience.org/library/genes/29126 | Drugs and targets |
| TUBA1A | Tubulin | 3 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7846 | Drugs and targets |
| TUBA1B | Tubulin | 3 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/10376 | Drugs and targets |
| TUBA1C | Tubulin | 3 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/84790 | Drugs and targets |
| TUBA3C | Tubulin | 3 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7278 | Drugs and targets |
| TUBA3E | Tubulin | 3 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/112714 | Drugs and targets |
| TUBA4A | Tubulin | 3 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7277 | Drugs and targets |
| TUBB | Tubulin | 3 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/203068 | Drugs and targets |
1 to 10 of 114
See all 114 targetsTrials96
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01265849 | Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity | Phase 3 | 928 | 2022-08-19 | Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Soft Palate | CYCLOPHOSPHAMIDE, INDOMETHACIN | Its record names the disease | ClinicalTrials.gov |
| NCT02952586 | Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100) | Phase 3 | 697 | 2021-02-24 | Squamous Cell Carcinoma of the Head and Neck | AVELUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02347332 | Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer | Phase 3 | 459 | 2019-02-04 | Recurrent or Metastatic Head and Neck Carcinoma | METHOTREXATE, VINFLUNINE | Its record names the disease | ClinicalTrials.gov |
| NCT02609386 | IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity | Phase 2 | 105 | 2024-01-30 | Squamous Cell Carcinoma of the Oral Cavity | CYCLOPHOSPHAMIDE, INDOMETHACIN, IRX-2, OMEPRAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT04649476 | Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma | Phase 2 | 68 | 2024-04-12 | Oral Squamous Cell Carcinoma | CAMRELIZUMAB, CISPLATIN, DOCETAXEL, FLUOROURACIL | Its record names the disease | ClinicalTrials.gov |
| NCT04137627 | Melatonin Effect in Combination With Neoadjuvant Chemotherapy to Clinical Response in Locally Advanced Oral Squamous Cell Carcinoma | Phase 3 | 50 | 2019-12-09 | Oral Squamous Cell Carcinoma, Neoadjuvant Chemotherapy | MELATONIN | Its record names the disease | ClinicalTrials.gov |
| NCT03692325 | Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia | Phase 2 | 33 | 2024-04-22 | Leukoplakia, Oral | NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02919683 | Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity | Phase 2 | 30 | 2020-07-31 | Head and Neck Cancer | IPILIMUMAB, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02949700 | Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma | Phase 1/2 | 26 | 2022-07-21 | Head and Neck Squamous Cell Carcinoma | METFORMIN | Its record names the disease | ClinicalTrials.gov |
| NCT00882583 | A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC | Phase 1 | 22 | 2017-02-23 | Head and Neck Cancer | CETUXIMAB, CISPLATIN, DASATINIB ANHYDROUS | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 96
See all 96 trialsComparisons in its trials16
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Avelumab + Standard of Care Chemotherapy (SOC CRT) vs Placebo + SOC CRT: deaths from any cause | 86 of 348 | 62 of 344 | 692 | NCT02952586 | Trial comparisons |
| Avelumab + Standard of Care Chemotherapy (SOC CRT) vs Placebo + SOC CRT: serious adverse events | 184 of 348 | 177 of 344 | 692 | NCT02952586 | Trial comparisons |
| Vinflunine Plus Methotrexate vs Methotrexate: deaths from any cause | 185 of 225 | 194 of 227 | 452 | NCT02347332 | Trial comparisons |
| Vinflunine Plus Methotrexate vs Methotrexate: serious adverse events | 106 of 225 | 81 of 227 | 452 | NCT02347332 | Trial comparisons |
| Regimen 1 vs Regimen 2: Event-free Survival (EFS)- Number of Participants With an Event | 31 of 70 | 15 of 35 | 105 | NCT02609386 | Trial comparisons |
| Regimen 1 vs Regimen 2: Overall Survival (OS)- Number of Participants With an Event | 19 of 70 | 11 of 35 | 105 | NCT02609386 | Trial comparisons |
| Regimen 1 vs Regimen 2: deaths from any cause | 19 of 70 | 11 of 35 | 105 | NCT02609386 | Trial comparisons |
| Regimen 1 vs Regimen 2: serious adverse events | 29 of 68 | 14 of 35 | 103 | NCT02609386 | Trial comparisons |
| Neoadjuvant PD-1 Blockade Alone vs Neoadjuvant PD-1 Blockade Plus TPF Induction Chemotherapy: deaths from any cause | 0 of 34 | 1 of 34 | 68 | NCT04649476 | Trial comparisons |
| Neoadjuvant PD-1 Blockade Alone vs Neoadjuvant PD-1 Blockade Plus TPF Induction Chemotherapy: serious adverse events | 2 of 34 | 11 of 34 | 68 | NCT04649476 | Trial comparisons |
1 to 10 of 16
See all 16 comparisons in its trialsPapers from its trials30
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004958
GET https://conductscience.org/api/diseases/v1/MONDO_0004958/drugs?page=2